CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 100 target
Drug / intervention
HQP1351drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03594422
NCT03594422Phase 1RecruitingOn TrackUpdated 2mo ago
Long Recruiting
CompareCT.gov

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.

Ascentage Pharma Group Inc.·interventional·Posted Jul 20, 2018·Updated Apr 9, 2026

In Brief

A Phase 1 clinical trial evaluating HQP1351 for Gastrointestinal Stromal Tumor (GIST) and Solid Tumor, Adult. Currently recruiting, targeting 100 participants across 6 sites.

Detailed Summary

This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult
CountriesChina
CollaboratorsHealthQuest Pharma Inc.

Timeline

Phase 1Recruiting
20192020202120222023202420252026202720282029
First PostedJul 20, 2018
Enrollment StartJul 11, 2018
Primary CompletionDec 1, 2027
Study CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 9.4 yearsPosted 7.9 years agoPrimary completion in 1.4 years

Interventions

HQP1351drug

HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.